Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Average Rating of “Moderate Buy” by Brokerages

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has been assigned an average recommendation of “Moderate Buy” from the seven research firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, three have given a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $18.75.

A number of equities research analysts have issued reports on the stock. Rodman & Renshaw assumed coverage on shares of Atara Biotherapeutics in a research note on Friday, December 20th. They set a “buy” rating and a $25.00 target price for the company. TD Cowen upgraded Atara Biotherapeutics to a “strong-buy” rating in a report on Friday, November 29th. RODMAN&RENSHAW raised Atara Biotherapeutics to a “strong-buy” rating in a report on Friday, December 20th. Finally, Canaccord Genuity Group raised their price objective on Atara Biotherapeutics from $13.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th.

Hedge Funds Weigh In On Atara Biotherapeutics

A number of hedge funds have recently added to or reduced their stakes in ATRA. Vestal Point Capital LP grew its stake in shares of Atara Biotherapeutics by 11.3% in the 3rd quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company’s stock valued at $1,014,000 after buying an additional 12,677 shares during the period. Cubist Systematic Strategies LLC bought a new stake in Atara Biotherapeutics in the second quarter worth about $79,000. State Street Corp lifted its position in shares of Atara Biotherapeutics by 52.3% during the 3rd quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock valued at $182,000 after buying an additional 7,680 shares during the last quarter. FMR LLC boosted its position in Atara Biotherapeutics by 41.7% during the third quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock worth $204,000 after purchasing an additional 7,381 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Atara Biotherapeutics in the second quarter worth $53,000. Institutional investors own 70.90% of the company’s stock.

Atara Biotherapeutics Stock Performance

Shares of ATRA stock opened at $18.00 on Tuesday. Atara Biotherapeutics has a one year low of $6.50 and a one year high of $39.50. The stock has a market capitalization of $103.68 million, a price-to-earnings ratio of -0.70 and a beta of 0.51. The company’s 50-day simple moving average is $11.90 and its 200-day simple moving average is $9.67.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.77) by $0.84. The business had revenue of $40.19 million for the quarter, compared to analyst estimates of $23.00 million. During the same quarter in the prior year, the firm posted ($16.50) earnings per share. As a group, research analysts forecast that Atara Biotherapeutics will post -12.12 EPS for the current year.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.